Jan. 5, 2007 — An announcement from AstraZeneca is expected soon about the company’s experimental heart drug AGI-1067, the company’s partner AtheroGenics Inc. hopes to present results from a pivotal Phase III clinical trial to the American College of Cardiology (ACC) meeting in New Orleans.
Jan. 5, 2007 — A report in the January issue of the Journal of the American College of Cardiology finds that as many as ...
Jan. 5, 2007 — MedicalCV, Inc., a cardiovascular surgery company, says it will amend its 510(k) submission for clearance ...
SPONSORED CONTENT — Studycast is a comprehensive imaging workflow system that allows healthcare professionals to work ...
Non-white, low-income patients without commercial insurance are more likely to delay diagnosis of peripheral vascular ...
AP reports that a Dec. 27 Medicare proposal may could double the number of hospitals authorized to implant the HeartMate ...
HMS Technologies, Inc. (HMS), the exclusive federal distributor for the commercial versions of the EZ-IO Emergency ...
Providing exceptional cardiovascular care for patients to achieve the best possible outcomes is the number one goal for ...
Dual-chamber pacing coupled with Boston Scientific's AV Search Hysteresis (AVSH) programming has the potential to reduce ...
A review by physicians at Tulane University School of Public Health and Tropical Medicine shows that Vitamin B12 ...
Heartwire cites results of a new study finding that current heart-failure performance measures, with the exception of ...
Cardiac positron emission tomography (PET) is growing in popularity among cardiologists because it provides the ability ...
Reuters reports that a study of military veterans suffering from post-traumatic stress disorder showed that more severe their anxiety, the greater their risk of heart disease. Adding to the long-recognized connection between stress and heart disease, researchers at the Harvard School of Public Health in Boston said that relationship existed among nearly 2,000 Boston-area veterans.
A new intravascular MRI catheter developed by Topspin Medical has received CE Mark approval, and the Israeli company ...
Implant Sciences Corp. a wholly-owned German subsidiary of CorNova, Inc., has received CE Mark marketing approval for ...
When performing radiofrequency (RF) ablation to treat cardiac arrhythmia, medical professionals must balance the safety ...
Swiss researchers may have discovered the reason drug-eluting stents cause thrombosis, and their study results are ...
The latest in thrombus removal devices from Possis has received FDA clearance — the new AngioJet Ultra Thrombectomy System is the next-generation, re-engineered version of the company’s AngioJet Rheolytic Thrombectomy System.
The first patients to receive a new, implanted heart-monitoring device underwent procedures recently at the Clinica ...